A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.
Journal: European Journal of Cancer
Volume: 39
Issue: 8
Pages: 1121-1128
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(03)00150-3
Abstract:No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP. © 2003 Elsevier Science Ltd. All rights reserved.
Source: Scopus
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.
Journal: Eur J Cancer
Volume: 39
Issue: 8
Pages: 1121-1128
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(03)00150-3
Abstract:No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m(2)/day for a maximum of 24 weeks) +/-MMC (7 mg/m(2) 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.
Source: PubMed
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.
Journal: EUROPEAN JOURNAL OF CANCER
Volume: 39
Issue: 8
Pages: 1121-1128
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(03)00150-3
Source: Web of Science (Lite)
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary
Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y. and Hilla, M.E.
Journal: European Journal of Cancer
Volume: 39
Pages: 1121-1128
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(03)00150-3
Abstract:No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.
Source: Manual
Preferred by: Tamas Hickish
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.
Journal: European journal of cancer (Oxford, England : 1990)
Volume: 39
Issue: 8
Pages: 1121-1128
eISSN: 1879-0852
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(03)00150-3
Abstract:No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m(2)/day for a maximum of 24 weeks) +/-MMC (7 mg/m(2) 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.
Source: Europe PubMed Central